Operating Income (Loss) of VBI Vaccines Inc/BC from 31 Dec 2015 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
VBI Vaccines Inc/BC quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Dec 2015 to 31 Mar 2024.
  • VBI Vaccines Inc/BC Operating Income (Loss) for the quarter ending 31 Mar 2024 was $11,752,000, a 40% increase year-over-year.
  • VBI Vaccines Inc/BC Operating Income (Loss) for the twelve months ending 31 Mar 2024 was $72,154,000, a 16% increase year-over-year.
  • VBI Vaccines Inc/BC annual Operating Income (Loss) for 2023 was $79,911,000, a 2.3% increase from 2022.
  • VBI Vaccines Inc/BC annual Operating Income (Loss) for 2022 was $81,820,000, a 20% decline from 2021.
  • VBI Vaccines Inc/BC annual Operating Income (Loss) for 2021 was $68,032,000, a 56% decline from 2020.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

VBI Vaccines Inc/BC Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $72,154,000 $11,752,000 +$7,757,000 +40% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $79,911,000 $13,361,000 +$8,078,000 +38% 01 Oct 2023 31 Dec 2023 10-K 16 Apr 2024 2023 FY
Q3 2023 $87,989,000 $10,069,000 +$11,489,000 +53% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $99,478,000 $36,972,000 -$14,069,000 -61% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $85,409,000 $19,509,000 -$3,589,000 -23% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $81,820,000 $21,439,000 -$569,000 -2.7% 01 Oct 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
Q3 2022 $81,251,000 $21,558,000 -$6,534,000 -43% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $74,717,000 $22,903,000 -$6,462,000 -39% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $68,255,000 $15,920,000 -$223,000 -1.4% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $68,032,000 $20,870,000 -$6,661,000 -47% 01 Oct 2021 31 Dec 2021 10-K 13 Mar 2023 2022 FY
Q3 2021 $61,371,000 $15,024,000 -$3,171,000 -27% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $58,200,000 $16,441,000 -$8,299,000 -102% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $49,901,000 $15,697,000 -$6,284,000 -67% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $43,617,000 $14,209,000 -$4,041,000 -40% 01 Oct 2020 31 Dec 2020 10-K 07 Mar 2022 2021 FY
Q3 2020 $39,576,000 $11,853,000 +$4,290,000 +27% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $43,866,000 $8,142,000 +$4,127,000 +34% 01 Apr 2020 30 Jun 2020 10-Q 02 Aug 2021 2021 Q2
Q1 2020 $47,993,000 $9,413,000 +$4,406,000 +32% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $52,399,000 $10,168,000 +$8,340,000 +45% 01 Oct 2019 31 Dec 2019 10-K 02 Mar 2021 2020 FY
Q3 2019 $60,739,000 $16,143,000 -$1,601,000 -11% 01 Jul 2019 30 Sep 2019 10-Q 02 Nov 2020 2020 Q3
Q2 2019 $59,138,000 $12,269,000 +$3,465,000 +22% 01 Apr 2019 30 Jun 2019 10-Q 31 Jul 2020 2020 Q2
Q1 2019 $62,603,000 $13,819,000 -$2,195,000 -19% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $60,408,000 $18,508,000 -$7,528,000 -69% 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q3 2018 $52,880,000 $14,542,000 -$5,401,000 -59% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $47,479,000 $15,734,000 -$7,422,000 -89% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $40,057,000 $11,624,000 -$2,777,000 -31% 01 Jan 2018 31 Mar 2018 10-Q 01 May 2019 2019 Q1
Q4 2017 $37,280,000 $10,980,000 -$2,315,000 -27% 01 Oct 2017 31 Dec 2017 10-K 25 Feb 2019 2018 FY
Q3 2017 $34,965,000 $9,141,000 -$1,401,000 -18% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $33,564,000 $8,312,000 -$2,430,000 -41% 01 Apr 2017 30 Jun 2017 10-Q 26 Jul 2018 2018 Q2
Q1 2017 $31,134,000 $8,847,000 -$6,284,000 -245% 01 Jan 2017 31 Mar 2017 10-Q 01 May 2018 2018 Q1
Q4 2016 $24,850,000 $8,665,000 01 Oct 2016 31 Dec 2016 10-K 26 Feb 2018 2017 FY
Q3 2016 $7,740,000 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2017 Q3
Q2 2016 $5,882,000 01 Apr 2016 30 Jun 2016 10-Q 31 Jul 2017 2017 Q2
Q1 2016 $2,563,000 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1

VBI Vaccines Inc/BC Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $79,911,000 +$1,909,000 +2.3% 01 Jan 2023 31 Dec 2023 10-K 16 Apr 2024 2023 FY
2022 $81,820,000 -$13,788,000 -20% 01 Jan 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
2021 $68,032,000 -$24,415,000 -56% 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2023 2022 FY
2020 $43,617,000 +$8,782,000 +17% 01 Jan 2020 31 Dec 2020 10-K 07 Mar 2022 2021 FY
2019 $52,399,000 +$8,009,000 +13% 01 Jan 2019 31 Dec 2019 10-K 02 Mar 2021 2020 FY
2018 $60,408,000 -$23,128,000 -62% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
2017 $37,280,000 -$12,430,000 -50% 01 Jan 2017 31 Dec 2017 10-K 25 Feb 2019 2018 FY
2016 $24,850,000 -$1,091,000 -4.6% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2018 2017 FY
2015 $23,759,000 01 Jan 2015 31 Dec 2015 10-K 26 Feb 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.